Abstract
Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Current Pharmaceutical Design
Title: Molecular Pharmacology of Non-L-type Calcium Channels
Volume: 11 Issue: 15
Author(s): Clinton J. Doering and Gerald W. Zamponi
Affiliation:
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Abstract: Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Export Options
About this article
Cite this article as:
Doering J. Clinton and Zamponi W. Gerald, Molecular Pharmacology of Non-L-type Calcium Channels, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021042
DOI https://dx.doi.org/10.2174/1381612054021042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Types of Voltage-Gated Calcium Channels: Molecular and Electrophysiological Views
Current Hypertension Reviews QSAR Studies for the Pharmacological Inhibition of Glycogen Synthase Kinase-3
Medicinal Chemistry The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry Structure-Activity Relationships for Serotonin Transporter and Dopamine Receptor Selectivity
Medicinal Chemistry Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research The Therapeutic Role of Electroencephalography in Deep Brain Stimulation in Intractable Epilepsy: A Recent Perspective
Recent Patents and Topics on Imaging (Discontinued) Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Book Review: “Dendrites- Third Edition”
CNS & Neurological Disorders - Drug Targets Application of Human Placental Villous Tissue Explants to Study ABC Transporter Mediated Efflux of 2,4-Dinitrophenyl-S-Glutathione
Current Pharmaceutical Biotechnology Semicarbazone Analogs as Anticonvulsant Agents: A Review
Central Nervous System Agents in Medicinal Chemistry Experimental Treatment Options in Absence Epilepsy
Current Pharmaceutical Design Could Event Related Potentials be a Key Prognostic Biomarker of Alzheimer’s Disease?
Current Alzheimer Research Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs
Current Pharmaceutical Design Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets Computer-Aided Drug Discovery and Design Targeting Ion Channels
Current Topics in Medicinal Chemistry Allele Frequency Distributions of the Drug Metabolizer Genes <i>CYP2C9*2</i>, <i>CYP2C9*3</i>, and <i>CYP2C19*17</i> in the Buginese Population of Indonesia
Current Pharmacogenomics and Personalized Medicine